Profile data is unavailable for this security.
About the company
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
- Revenue in USD (TTM)46.24m
- Net income in USD-354.11m
- Incorporated2013
- Employees500.00
- LocationRecursion Pharmaceuticals Inc41S Rio Grande StreetSALT LAKE CITY 84101United StatesUSA
- Phone+1 (385) 269-0203
- Fax+1 (801) 581-7895
- Websitehttps://www.recursion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.89bn | 167.00 | 29.79 | 3.37 | 18.79 | 4.61 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 1.96bn | 186.00 | -- | 2.76 | -- | 24.68 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Arvinas Inc | 71.30m | -354.80m | 1.99bn | 445.00 | -- | 3.26 | -- | 27.95 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.00bn | 500.00 | -- | 4.98 | -- | 43.23 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 2.00bn | 436.00 | -- | 2.19 | -- | 5.55 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 2.02bn | 268.00 | -- | 4.56 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Myriad Genetics, Inc. | 774.20m | -234.60m | 2.02bn | 2.70k | -- | 2.66 | -- | 2.61 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.06bn | 7.70k | -- | -- | 19.36 | 0.8263 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.06bn | 1.76k | 14.55 | 3.07 | 10.27 | 3.05 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.16bn | 55.00 | -- | 6.08 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.16bn | 160.00 | -- | 2.57 | -- | 355.60 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.17bn | 497.00 | -- | 5.99 | -- | 8.15 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.19bn | 570.00 | -- | 5.33 | -- | 8.00 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Data as of Jun 07 2024. Currency figures normalised to Recursion Pharmaceuticals Inc's reporting currency: US Dollar USD
59.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 24.59m | 11.81% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 24.07m | 11.56% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 15.75m | 7.56% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 10.59m | 5.08% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 10.36m | 4.98% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 10.35m | 4.97% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 9.24m | 4.43% |
| MIC Capital Management UK LLPas of 31 Mar 2024 | 8.45m | 4.06% |
| MDC Capital Management LLCas of 12 Apr 2024 | 7.06m | 3.39% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.53m | 1.70% |
More ▼
Data from 31 Dec 2023 - 12 Apr 2024Source: FactSet Research Systems Inc.
